Physician profile
Mark A Testa
NPI 1043205370
$18,364.71
in general payments reported to CMS, 2019-2025
58 companies · $3,409 in 2025
The $3,409 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $2,636 · 2021: $2,873 · 2022: $3,083 · 2023: $2,369 · 2024: $2,527 · 2025: $3,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,293 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,293.15 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,527.74 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals Lp | $2,046.78 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $2,000.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,577.16 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Allergan, INC. | $1,107.67 | 2019-2020 | |
| Lilly USA, LLC | $879.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $718.01 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $708.86 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $557.16 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $532.63 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $493.58 | 2019-2025 | Veozah, Myrbetriq |
| Kowa Pharmaceuticals America, INC. | $395.73 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Novartis Pharmaceuticals Corporation | $365.60 | 2019-2023 | |
| Amgen INC. | $340.29 | 2020-2025 | Evenity, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.05 | 2019-2024 | Xifaxan |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $298.01 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $295.50 | 2023-2025 | Ingrezza |
| Abbott Laboratories | $271.02 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Amarin Pharma, INC. | $269.80 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $194.74 | 2019-2025 | |
| Almatica Pharma LLC | $175.49 | 2021-2025 | Loreev Xr |
| Gilead Sciences, INC. | $169.84 | 2022-2024 | |
| Exact Sciences Corporation | $164.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160.57 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $153.52 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Hikma Pharmaceuticals USA | $128.58 | 2019-2023 | Mitigare, Ryaltris |
| Shield Therapeutics INC | $126.59 | 2023-2025 | Accrufer |
| E.R. Squibb & Sons, L.L.C. | $105.21 | 2019-2025 | Eliquis, Camzyos |
| Lundbeck LLC | $98.59 | 2023-2024 | Rexulti |
| Axsome Therapeutics, INC. | $98.33 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $97.50 | 2022-2025 | Spravato |
| Daiichi Sankyo INC. | $96.57 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $78.34 | 2020-2024 | Linzess |
| Inspire Medical Systems, INC. | $74.65 | 2025 | Inspire |
| Evoke Pharma, INC. | $73.19 | 2022-2025 | Gimoti |
| Sumitomo Pharma America, INC. | $66.21 | 2024-2025 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $64.56 | 2022-2024 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $51.84 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $44.43 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $43.30 | 2021 | |
| Esperion Therapeutics, INC. | $42.37 | 2021-2024 | Nexletol |
| Amneal Pharmaceuticals LLC | $35.33 | 2023 | Lyvispah |
| Takeda Pharmaceuticals U.S.A., INC. | $32.90 | 2021-2024 | Trintellix |
| Sanofi Pasteur INC. | $32.26 | 2019 | |
| Philips North America LLC | $29.50 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $29.46 | 2021-2022 | |
| Eisai INC. | $23.35 | 2021 | |
| Clarus Therapeutics INC. | $20.06 | 2021 | |
| Scilex Pharmaceuticals INC. | $16.61 | 2024 | |
| Corcept Therapeutics | $16.59 | 2024 | Korlym |
| Verona Pharma, INC. | $15.34 | 2025 | Ohtuvayre |
| Phadia US INC. | $14.52 | 2019 | |
| Idorsia Pharmaceuticals US INC | $14.45 | 2023 | Quviviq |
| Halozyme INC | $14.30 | 2023 | |
| Acadia Pharmaceuticals INC | $13.85 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.35 | 2024 | Nuzyra |
| Circassia INC. | $13.23 | 2020 | |
| Eyevance Pharmaceuticals LLC | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Testa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.